Shopping Cart
Remove All
Your shopping cart is currently empty
Tafolecimab (IBI-306) is a humanised monoclonal antibody targeting PCSK9, capable of improving multiple lipid parameters (LDL, LDL-C, LDL-CFB, etc.), suitable for studying hypercholesterolaemia and mixed hyperlipidaemia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,570 | - | In Stock | |
| 25 mg | $2,330 | - | In Stock | |
| 50 mg | $3,130 | - | In Stock |
| Description | Tafolecimab (IBI-306) is a humanised monoclonal antibody targeting PCSK9, capable of improving multiple lipid parameters (LDL, LDL-C, LDL-CFB, etc.), suitable for studying hypercholesterolaemia and mixed hyperlipidaemia. |
| Synonyms | IBI-306, IBI306 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PCSK9 |
| Molecular Weight | 145.07 kDa |
| Cas No. | 2225109-03-3 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.